bromodeoxyuridine has been researched along with Diabetic Neuropathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, FM; Bolz, M; Chopp, M; Cui, Y; Liu, Z; Lu, M; Szalad, A; Wang, L; Zhang, L; Zhang, RL; Zhang, ZG | 1 |
| Bampton, ET; Gumy, LF; Tolkovsky, AM | 1 |
2 other study(ies) available for bromodeoxyuridine and Diabetic Neuropathies
| Article | Year |
|---|---|
Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain-Derived Neurotrophic Factor; Bromodeoxyuridine; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Complications; Diabetic Neuropathies; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Nerve Tissue Proteins; Neural Conduction; Pain Measurement; Pain Threshold; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Receptors, Leptin; RNA, Small Interfering; Schwann Cells; Sciatic Neuropathy; Sildenafil Citrate; Sulfones; Time Factors; Transfection | 2011 |
Hyperglycaemia inhibits Schwann cell proliferation and migration and restricts regeneration of axons and Schwann cells from adult murine DRG.
Topics: Animals; Bromodeoxyuridine; Cell Differentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Diabetic Neuropathies; G1 Phase; Ganglia, Spinal; Glucose; Growth Cones; Hyperglycemia; Mice; Mice, Knockout; Myelin Sheath; Nerve Regeneration; Neuregulin-1; Rats; Retinoblastoma Protein; Schwann Cells; Wallerian Degeneration | 2008 |